Interleukin 31 and skin diseases: A systematic review

Gangemi, Sebastiano; Quartuccio, S.; Casciaro, Marco; Trapani, Giovanni Di; Minciullo, Paola Lucia; Imbalzano, Egidio

doi:10.2500/aap.2017.38.4080

Cited by 37 publications

(34 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Interleukin IL-31 binds to a receptor on peripheral nerve fibers, and has been shown to link inflammation with pruritus in the skin, with recent studies demonstrating that IL-31 mRNA expression is present in skin samples of inflammatory diseases, such as AD and allergic contact dermatitis [13]. IL-31 plays a major part in causation of pruritus and worsening of the course in AD [26,27], and it is significantly overexpressed in pruritic atopy compared with non-pruritic psoriatic skin inflammation [25]. Subcutaneous, intradermal or intravenous administration of IL-31 into normal mice induces severe pruritus [28].…”

Section: Discussionmentioning

confidence: 99%

The impact of medium dose UVA1 phototherapy on pruritus, DLQI and SCORAD index in patients with atopic dermatitis

Malinowska¹,

Woźniacka²,

Bogaczewicz³

2020

pdia

View full text Add to dashboard Cite

Introduction: Atopic dermatitis (AD) is featured by pruritus, which causes diminished quality of life. Little clinical data exists concerning the use, efficacy and side effects of UVA1 phototherapy in AD patients. Aim: To determine the effectiveness of medium-dose UVA1 phototherapy in AD treatment. Material and methods: Thirty-six patients with AD were irradiated with medium-dose UVA1 (45 J/cm 2) as monotherapy for 4 weeks for a total of 20 sessions (daily irradiations during weekdays only). Clinical status was evaluated with the visual analogue scale for pruritus, Dermatology Life Quality Index (DLQI) for evaluating general well-being and the SCORAD index. All parameters were measured twice: before and after phototherapy. Results: UVA1 phototherapy resulted in a significant (p < 0.001) decrease in pruritus, improvement in DLQI (p < 0.001) and SCORAD (p < 0.001). Before phototherapy, the intensity of pruritus and SCORAD index correlated with DLQI (r = 0.34, p < 0.05 and 0.61, p < 0.05, respectively). Similarly, after irradiation, pruritus correlated with DLQI, and SCORAD index correlated with DLQI (r = 0.51, p < 0.05 and r = 0.55, p < 0.05, respectively). No severe adverse effects were noted during the study. Conclusions: Phototherapy with medium-dose UVA1 irradiation exerts a significant antipruritic effect, decreases the severity of the disease and improves the quality of life of AD patients. This technique can therefore be used as a safe and effective treatment method.

show abstract

Section: Discussionmentioning

confidence: 99%

The impact of medium dose UVA1 phototherapy on pruritus, DLQI and SCORAD index in patients with atopic dermatitis

Malinowska¹,

Woźniacka²,

Bogaczewicz³

2020

pdia

View full text Add to dashboard Cite

show abstract

“…30 The role of IL-31 in skin diseases was recently reviewed. 28,31,32 Here we showed that human-cultured LAD2 MCs secreted IL-31 in response to IL-33 and that this effect was augmented by SP, IgE/anti-IgE, or their combination, and was further increased by IL-4.…”

mentioning

confidence: 84%

Interleukin 33 and interleukin 4 regulate interleukin 31 gene expression and secretion from human laboratory of allergic diseases 2 mast cells stimulated by substance P and/or immunoglobulin E

Petra

Tsilioni

Taracanova

et al. 2018

allergy asthma proc

View full text Add to dashboard Cite

show abstract

“…Interleukins (ILs) are cytokines involved in immune regulation, and abnormal production may increase susceptibility to AE. Two SRs studied the importance of IL‐31 in AE, and concluded that expression in lesional skin and serum levels is increased in patients with AE . Targeting IL‐31 may therefore be a potential avenue for future AE treatments, particularly for reducing pruritus, which is associated with IL‐31.…”

Section: Aetiology and Biomarkersmentioning

confidence: 99%

What’s new in atopic eczema? An analysis of systematic reviews published in 2017. Part 2: epidemiology, aetiology and risk factors

et al. 2019

View full text Add to dashboard Cite

This article forms part of a series of annual updates that summarizes the evidence base for atopic eczema (AE). It provides a summary of key findings from 28 systematic reviews that were published or indexed during 2017, and focuses on the epidemiology, aetiology and risk factors of AE. AE is the largest single contributor to morbidity associated with skin disease worldwide, once mortality has been excluded. There is a high prevalence of sleep disturbance in individuals with AE and they take more sick leave than controls. While there is a lack of skin bacterial diversity in patients with AE, there is a relative abundance of Staphylococcus aureus and Staphylococcus epidermidis. Compared with controls, affected individuals more often show an IgE response to S. aureus antigens and have higher serum interleukin-31 levels. Early antibiotic exposure, environmental pollutants, maternal atopy and food allergy are associated with an increased risk of AE, and very preterm birth is associated with decreased risk. Patients with AE have a reduced risk of meningioma, but are more likely to develop attention-deficit hyperactivity disorder compared with controls. Patients with eosinophilic oesophagitis are significantly more likely than unaffected individuals to have AE. There is no significant overall association between AE and allergic contact dermatitis (ACD), and in children referred for patch testing, ACD was more common in those without AE. Hand eczema is more prevalent in patients with AE. There is no association between AE and Type 2 diabetes, hypertension, stroke or myocardial infarction.

show abstract

Interleukin 31 and skin diseases: A systematic review

Cited by 37 publications

References 0 publications

The impact of medium dose UVA1 phototherapy on pruritus, DLQI and SCORAD index in patients with atopic dermatitis

The impact of medium dose UVA1 phototherapy on pruritus, DLQI and SCORAD index in patients with atopic dermatitis

Interleukin 33 and interleukin 4 regulate interleukin 31 gene expression and secretion from human laboratory of allergic diseases 2 mast cells stimulated by substance P and/or immunoglobulin E

What’s new in atopic eczema? An analysis of systematic reviews published in 2017. Part 2: epidemiology, aetiology and risk factors

Contact Info

Product

Resources

About